Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment - Experienced, HIV-infected individuals: Recent data and consensus recommendations

Mike Youle*, Schlomo Staszweski, Bonaventura Clotet, José Ramon Arribas, Anders Blaxhult, Giaampiero Carosi, Edwin De Jesus, Gianni Di Perri, Vicente Estrada, Martin Fisher, Colin Kovacs, Ranjababu Kulasegaram, Adriano Lazzarin, Debbie Marriot, Leopoldo Moñoz, Jacques Reynes, Peter Shalit, Jihad Slim, Chris Tsoukas, Anthony VaccaroJosé Vera

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Recent data from clinical trials investigating the efficacy of enfuvirtide, a fusion inhibitor, in treatment-experienced patients have revealed that the addition of enfuvirtide (ENF) to an active boosted protease inhibitor regimen doubles the rate of virological response. At week 48 of the TORO studies, 55% of patients previously naive to and receiving lopinavir/ritonavir (LPV/r) with ENF achieved a viral load of <400 copies/mL compared with 24% of patients treated with LPV/r alone. At week 24 of the RESIST studies, 70% of previously ENF-naive patients who took both ENF and tipranavir/ritonavir (TPV/r) achieved a ≥1 log10 reduction in viral load compared with 37% of such patients treated with TPV/r alone. Similarly, concomitant use of TMC114/ritonavir (TMC114/r) with ENF, compared with TMC114/r alone, increased the number of patients with <50 copies/mL from 46% to 64% in a combined 24-week analysis from the POWER trials. Data from these trials suggest that combining one agent from a new class with a new agent from a previously exposed class offers a greater chance of achieving full virological control than either type of agent alone. Undetectable viraemia should be the primary objective for treatment-experienced patients requiring a switch in therapy, and the present data support the combination of an active boosted protease inhibitor with an agent from a new class (e.g., ENF) for triple-class-experienced patients.

Original languageEnglish (US)
Pages (from-to)86-96
Number of pages11
JournalHIV Clinical Trials
Volume7
Issue number2
DOIs
StatePublished - Mar 2006

Keywords

  • Active boosted PI
  • Enfuvirtide
  • Triple-class-experienced

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment - Experienced, HIV-infected individuals: Recent data and consensus recommendations'. Together they form a unique fingerprint.

Cite this